Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11821753rdf:typepubmed:Citationlld:pubmed
pubmed-article:11821753lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:11821753lifeskim:mentionsumls-concept:C0012984lld:lifeskim
pubmed-article:11821753lifeskim:mentionsumls-concept:C0472699lld:lifeskim
pubmed-article:11821753lifeskim:mentionsumls-concept:C0021081lld:lifeskim
pubmed-article:11821753lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:11821753lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:11821753lifeskim:mentionsumls-concept:C0388088lld:lifeskim
pubmed-article:11821753pubmed:issue2lld:pubmed
pubmed-article:11821753pubmed:dateCreated2002-1-31lld:pubmed
pubmed-article:11821753pubmed:abstractTextBACKGROUND: Stable mixed donor/host hematopoietic chimerism was almost uniformly achieved in dogs given 200 cGy total body irradiation (TBI) before, and a short course of immunosuppression after, transplantation of marrow from dog leukocyte antigen-identical littermates, but was transient when the TBI dose was decreased to 100 cGy. Here, we examined whether stable engraftment could be achieved in five dogs given FTY720 (days -5 and -4), followed by 100 cGy TBI, dog leukocyte antigen-identical marrow grafts, and mycophenolate mofetil/cyclosporine. RESULTS AND CONCLUSIONS: Although all five dogs showed initial engraftment, four dogs rejected their grafts within 11 weeks, whereas one dog was euthanized on day 17 due to enteritis. This was not different from the control dogs not given FTY720 (P=0.32). Thus, FTY720 failed to enhance allogeneic engraftment in this model, perhaps due to in vivo T-cell depletion of the graft resulting from sequestration of donor lymphocytes in host central lymphoid tissues.lld:pubmed
pubmed-article:11821753pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11821753pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11821753pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11821753pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11821753pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11821753pubmed:languageenglld:pubmed
pubmed-article:11821753pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11821753pubmed:citationSubsetIMlld:pubmed
pubmed-article:11821753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11821753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11821753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11821753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11821753pubmed:statusMEDLINElld:pubmed
pubmed-article:11821753pubmed:monthJanlld:pubmed
pubmed-article:11821753pubmed:issn0041-1337lld:pubmed
pubmed-article:11821753pubmed:authorpubmed-author:XunChang-Qing...lld:pubmed
pubmed-article:11821753pubmed:authorpubmed-author:LittleMarie-T...lld:pubmed
pubmed-article:11821753pubmed:authorpubmed-author:ZellmerEustac...lld:pubmed
pubmed-article:11821753pubmed:authorpubmed-author:YuCongClld:pubmed
pubmed-article:11821753pubmed:authorpubmed-author:ZauchaJan MJMlld:pubmed
pubmed-article:11821753pubmed:authorpubmed-author:SaleGeorge...lld:pubmed
pubmed-article:11821753pubmed:authorpubmed-author:StorerBarryBlld:pubmed
pubmed-article:11821753pubmed:authorpubmed-author:StorbRainerRlld:pubmed
pubmed-article:11821753pubmed:issnTypePrintlld:pubmed
pubmed-article:11821753pubmed:day27lld:pubmed
pubmed-article:11821753pubmed:volume73lld:pubmed
pubmed-article:11821753pubmed:ownerNLMlld:pubmed
pubmed-article:11821753pubmed:authorsCompleteYlld:pubmed
pubmed-article:11821753pubmed:pagination310-3lld:pubmed
pubmed-article:11821753pubmed:dateRevised2008-6-5lld:pubmed
pubmed-article:11821753pubmed:meshHeadingpubmed-meshheading:11821753...lld:pubmed
pubmed-article:11821753pubmed:meshHeadingpubmed-meshheading:11821753...lld:pubmed
pubmed-article:11821753pubmed:meshHeadingpubmed-meshheading:11821753...lld:pubmed
pubmed-article:11821753pubmed:meshHeadingpubmed-meshheading:11821753...lld:pubmed
pubmed-article:11821753pubmed:meshHeadingpubmed-meshheading:11821753...lld:pubmed
pubmed-article:11821753pubmed:meshHeadingpubmed-meshheading:11821753...lld:pubmed
pubmed-article:11821753pubmed:meshHeadingpubmed-meshheading:11821753...lld:pubmed
pubmed-article:11821753pubmed:meshHeadingpubmed-meshheading:11821753...lld:pubmed
pubmed-article:11821753pubmed:meshHeadingpubmed-meshheading:11821753...lld:pubmed
pubmed-article:11821753pubmed:year2002lld:pubmed
pubmed-article:11821753pubmed:articleTitleWhat role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation?lld:pubmed
pubmed-article:11821753pubmed:affiliationClinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, Seattle, WA 98109-1024, USA.lld:pubmed
pubmed-article:11821753pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11821753pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:11821753pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11821753lld:pubmed